STAT has published a new edition of its twice-weekly newsletter covering politics and healthcare policy. The issue examines health and medicine developments under the headline "Winners, losers, and MAHA." Full access to the text remains restricted to paying members of the platform. Subscribers to the service also receive additional news alerts, policy analysis, events, and other specialized newsletters.
Key points
Full political and healthcare policy coverage in this edition requires a paid STAT+ subsc…: Full political and healthcare policy coverage in this edition requires a paid STAT+ subscription.
Subscribers receive broader access to events, newsletters, news alerts, and ongoing polic…: Subscribers receive broader access to events, newsletters, news alerts, and ongoing policy analysis.
The organization continues its regular twice-weekly reporting on health policy developmen…: The organization continues its regular twice-weekly reporting on health policy developments in Washington.
Sources checked by our analysis pipeline: 1
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Welp.
Send news tips and a life jacket to [email protected] or John_Wilkerson.07 on Signal.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Healthcare facilities nationwide are confronting severe financial and operational pressures as shifting policy environments threaten patient access to care. Reductions in Medicaid funding alongside widespread drops in insurance enrollment will place major strain on provider budgets. Institutions must navigate these mounting resource deficits while attempting to sustain their standard service levels.
Chinese regulatory authorities are imposing fresh restrictions on investigator-initiated trials following recent patient fatalities during clinical testing. This policy change curtails an avenue that international drug developers long relied on for rapid and affordable early-phase human studies. As a consequence, American biotechnology firms are losing a dependable shortcut to accelerate their clinical development pipelines.
An individual perspective outlines the sensory and physical realities associated with wearing hearing technology in both ears. The account details personal observations regarding the psychophysics experienced by a bilateral cochlear device recipient. Such insights offer meaningful context into how auditory stimuli are processed by implant recipients in daily life.